Tag: directors

Reference is made to the stock exchange announcement published by Prosafe SE ("Prosafe" or the "Company") on 24 April 2025 where it was announced that Prosafe had agreed the terms of a recapitalization (the "Recapitalization") which, inter alia, includes a recapitalization of USD 193 million into 321,635,718 new shares in the Company (the "New Shares") and an offering of up to 17,868,651 warrants to shareholders in the Company as of 16 May 2025 as registered in the Euronex Securities Oslo VPS on the record date 20 May 2025 (the "Warrants"), subject to final approval being obtained by all lenders.

FORM 8.3

The Board of Directors of Ayvens is pleased to announce the appointment of Philippe de Rovira as Chief Executive Officer (“Directeur Général”) following the recommendation of the Nomination Committee as part of its succession planning exercise. This appointment will become effective on 1st December 2025. Philippe de Rovira is due to be appointed by cooptation as member of the Board of Directors of Ayvens upon his taking responsibility as Chief Executive Officer of Ayvens.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Optiva Inc. (TSX: OPT) ("Optiva" or the "Company"), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced that it has entered into a support agreement (the "Support Agreement") with holders ("Noteholders") of approximately 85% of its outstanding principal amount of 9.75% senior secured PIK toggle notes due July 20, 2025 (the "Notes").

NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).